Stock Ratings / Health Care / SKIN / dividends

DAVI (47) LNSR (24) QTEX (31) MBOT (41) ⌘ Pro Terminal →

SkinHealth Systems Inc. (Class A) (SKIN) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is SKIN trading relative to its 50-day, 200-day, and 52-week technical levels?

SKIN last traded at $9.94 (-2.07% on volume of 75,329 shares), positioning the stock -20.35% below its 50-day simple moving average ($12.48) and -40.55% below its 200-day simple moving average ($16.72). Across its 52-week range of $9.68 to $34.80, SKIN sits at the 1.0% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.70 to $11.18).

Q: Does SKIN pay a dividend and is it safe?

SkinHealth Systems Inc. (Class A) (SKIN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$9.94 -2.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.88

SkinHealth Systems Inc. (Class A) (SKIN) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $66.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SKIN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SKIN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, SkinHealth Systems Inc. (Class A) (NASDAQ: SKIN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.94 (-2.07% 1D, market cap $66.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SKIN ranks #648 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SKIN compare to DAVI and LNSR in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), SKIN carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 65.3%, and ROIC of -26.9%. By comparison, DAVI (Davion Healthcare Plc) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $67.3M) and LNSR (LENSAR Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M). Among the 5-stock peer group, SKIN leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SKIN?

▼

Per SKIN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818093), SkinHealth Systems Inc. (Class A) generated $300.8M in revenue (-10.0% YoY), -$9.5M in net income, and $37.2M in free cash flow against $499.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.88 (-0.56%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 12.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SKIN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY SKIN SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 12.4% FCF Margin ($37.2M FCF) & 65.3% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (22% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$11.00-4% Next Q

Q2 (-2Q)

Grade D$10.56+3% Next Q

Q3 (-1Q)

Grade E$10.88-8.6% Next Q

Current

Grade D-$9.94-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SKIN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SKIN currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.48) and Max Pain ($10.44) forces dealer call-delta covering toward $36.54.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SKIN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SKIN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SKIN)

✓Walkthrough of SKIN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SKIN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.67%🛡️ HOLDING TREND SUPPORT

2026-10-30O $10.26H $10.26L $9.68C $9.94VOL 75.3K

RES: $12.40SUP: $9.61SMA50: $12.48SMA200: $16.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SKIN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SKIN Butterfly Map → + Track SKIN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -10.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SKIN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SKIN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SKIN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SKIN)

Health Care Rank #648 of 1016 ⚔️ DAVI vs SKIN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SKIN vs. DAVI, LNSR, QTEX, MBOT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SkinHealth Systems Inc. (Class A) (SKIN) ranks #648 by composite RQD confidence (36/100, grade D-) and #716 by equity capitalization ($66.0M). Within this direct 5-issuer industry benchmark cohort, SKIN leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DAVI currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SKIN at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SKIN ACTIVE SkinHealth Systems Inc. (Class A)	D-	36/100	—	65.3%	-26.9%	-2.07%	$66.0M	Benchmark Subject
DAVI Davion Healthcare Plc	D	47/100	—	—	—	-37.55%	$67.3M	/davi-vs-skin →
LNSR LENSAR Inc.	E	24/100	—	39.4%	-35.0%	-2.18%	$73.3M	/lnsr-vs-skin →
QTEX QTREX Quantum Ltd.	E	31/100	—	0.7%	-35.0%	-7.58%	$73.9M	/qtex-vs-skin →
MBOT Microbot Medical Inc.	D-	41/100	—	—	-15.8%	-2.68%	$75.2M	/mbot-vs-skin →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818093

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SkinHealth Systems Inc. (Class A) (SKIN) reported GAAP revenue of $300.8M (-10.0% vs. FY2024 revenue of $334.3M , and -24.4% cumulative change since FY2023) , GAAP net income of -$9.5M, operating cash flow of $37.5M, and free cash flow of $37.2M (+141.8% YoY). On the balance sheet, SKIN closed FY2025 with $499.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$300.8M	-$9.5M	$37.5M	$37.2M	$499.8M	—
FY2024 (FY)	2024-12-31	$334.3M	-$29.1M	$16.1M	$15.4M	$685.7M	—
FY2023 (FY)	2023-12-31	$398.0M	-$100.1M	$21.8M	$21.8M	—	—

3. SKIN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SKIN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SKIN compare to DAVI and LNSR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SKIN?

Where is SKIN trading relative to its 50-day, 200-day, and 52-week technical levels?

SKIN last traded at $9.94 (-2.07% on volume of 75,329 shares), positioning the stock -20.35% below its 50-day simple moving average ($12.48) and -40.55% below its 200-day simple moving average ($16.72). Across its 52-week range of $9.68 to $34.80, SKIN sits at the 1.0% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.70 to $11.18).

SKIN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does SKIN pay a dividend and is it safe?

SkinHealth Systems Inc. (Class A) (SKIN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SKIN RQD Cockpit SKIN 12M Forecast SKIN Earnings & Move SKIN Dividends & DRIP SKIN Insiders & 13F SKIN Whale Options SKIN Profit Sankey SKIN News & Why